文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

局部晚期前列腺癌:放疗剂量递增或延长雄激素抑制对远处进展的影响(TROG 03.04 RADAR 10年数据)

Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-01-01

TROG 03.04 RADAR试验纳入1051例局部晚期前列腺癌患者,随机接受6或18个月雄激素抑制(AS)±唑来膦酸,并按剂量递增方案分层接受66、70、74 Gy外照射或46 Gy外照射+高剂量率近距离放疗推量。

核心结论

  • 与6个月AS相比,18个月AS独立于放疗剂量显著降低DP。
  • 接受HDRB治疗的患者从更长疗程AS中获得显著获益。
  • HDRB较剂量递增EBRT改善肿瘤学结局的证据需随机试验确认。

研究设计与样本

  • TROG 03.04 RADAR随机试验,局部晚期前列腺癌患者随机接受6或18个月AS±18个月唑来膦酸。
  • 试验通过随机化分层纳入剂量递增方案,剂量选项为66、70、74 Gy EBRT或46 Gy EBRT+HDRB。
  • 1071例随机受试者中1051例纳入本分析,主要终点为DP。

主要发现

  • 亚组分析中,较长AS在70 Gy和HDRB组显著降低DP,在66 Gy和74 Gy组未显著。
  • 10年调整累积DP发生率:66 Gy组26.1%(95%CI 18.9%-33.2%)、70 Gy组26.7%(22.9%-30.6%)、74 Gy组24.9%(20.0%-29.8%)、HDRB组19.7%(15.5%-23.8%)。

关键数值与推荐

  • 10年DP累积发生率:66 Gy 26.1%(18.9%-33.2%)、70 Gy 26.7%(22.9%-30.6%)、74 Gy 24.9%(20.0%-29.8%)、HDRB 19.7%(15.5%-23.8%)。

临床怎么用

  • 局部晚期前列腺癌患者可考虑18个月AS以降低远处进展风险,该效应独立于放疗剂量。
  • 接受HDRB治疗的患者可能从更长疗程AS中显著获益。
  • HDRB较剂量递增EBRT的肿瘤学优势需随机试验进一步确认后再常规推荐。

局限性

  • HDRB与剂量递增EBRT的比较非随机试验直接验证,需随机试验确认。
  • 亚组分析中较长AS的DP获益仅在70 Gy和HDRB组显著,其他剂量组未显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To clarify the relative effects of duration of androgen suppression (AS) and radiation dose escalation (RDE) on distant progression (DP) in men with locally advanced prostate cancer. METHODS AND MATERIALS: Participants with locally advanced prostate cancer in the TROG 03.04 RADAR trial were randomized to 6 or 18 months AS ± 18 months zoledronic acid (Z). The trial incorporated a RDE program by stratification at randomization and dosing options were 66, 70, or 74 Gy external beam radiation therapy (EBRT), or 46 Gy EBRT plus high-dose-rate brachytherapy boost (HDRB). The primary endpoint for this study was distant progression (DP). Secondary endpoints included local progression, bone progression, prostate cancer-specific mortality and all-cause mortality. Effect estimates for AS duration and RDE were derived using Fine and Gray competing risk models adjusting for use of Z, age, tumor stage, Gleason grade group, prostate-specific antigen, and treatment center. Cumulative incidence at 10 years was estimated for each RDE group. RESULTS: A total of 1051 out of 1071 randomized subjects were eligible for inclusion in this analysis. Compared with 6 months AS, 18 months AS significantly reduced DP independently of radiation dose (subhazard ratio 0.70; 95% confidence interval [CI], 0.56-0.87; P = .002). No statistically significant interaction between effect of AS duration and RT dose was observed (Wald test P = .76). In subgroup analyses, DP was significantly reduced by the longer duration of AS in the 70 Gy and HDRB groups but not in the 66 Gy and 74 Gy. Compared with 70 Gy, HDRB significantly reduced DP (subhazard ratio 0.68 [95% CI, 0.57-0.80]; P < .0001) independently of AS duration. At 10 years, adjusted cumulative incidences were 26.1% (95% CI, 18.9%-33.2%), 26.7% (22.9%-30.6%), 24.9% (20.0%-29.8%) and 19.7% (15.5%-23.8%) for DPs in the respective radiation dose groups. CONCLUSIONS: Compared with 6 months AS, 18 months AS reduced DP independently of radiation dose. Men treated with HDRB gained a significant benefit from a longer duration of AS. Evidence of improved oncologic outcomes for HDRB compared with dose-escalated EBRT needs to be confirmed in a randomized trial.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Joseph D, Denham JW, Steigler A, et al. Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial. Int J Radiat Oncol Biol Phys. 2020. PMID: 32092343. doi:10.1016/j.ijrobp.2019.11.415

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。